[ad_1]
The study participant’s illness will now be reviewed and evaluated by an independent group of experts and internal physicians. Initially there was no further information about the sick test person with reference to their privacy.
Johnson & Johnson also announced that it was not always immediately obvious whether a participant had received the study treatment or a placebo. “Adverse events,” such as illness or accidents, are expected components of each clinical study.
On September 23, the company began the final and crucial phase of clinical trials. In a phase III study with up to 60,000 volunteers on three continents, the safety and efficacy of the candidate vaccine called JNJ-78436735 had to be tested. The specialty of the remedy is that only one dose should offer sufficient protection. The company expected the first doses of the vaccine to be available “for emergency use” in early 2021.
Several manufacturers have started the required mass testing prior to approval with tens of thousands of test subjects. Most manufacturers assume that you need to get vaccinated twice to protect against coronavirus. So far, no candidate vaccine has been shown to actually protect against corona infection.
Last week, the EU Commission obtained the subscription rights for a future Johnson & Johnson vaccine: the EU authority entered into contracts with the Belgian subsidiary of the US company for the possible delivery of vaccines to 200 million people. There is also an option for another 200 million people. For vaccines that are still in development, the Commission had already signed similar contracts with AstraZeneca and Sanofi-GSK, which are also testing promising candidates. However, none of these substances have been approved yet.
